Picton Mahoney Asset Management Raises Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Picton Mahoney Asset Management increased its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 34.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 905 shares of the medical research company’s stock after buying an additional 230 shares during the period. Picton Mahoney Asset Management’s holdings in Charles River Laboratories International were worth $213,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. VisionPoint Advisory Group LLC grew its holdings in shares of Charles River Laboratories International by 105.7% in the third quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 74 shares in the last quarter. Headlands Technologies LLC bought a new position in Charles River Laboratories International during the third quarter valued at $37,000. Operose Advisors LLC purchased a new position in shares of Charles River Laboratories International in the 3rd quarter worth $42,000. Venturi Wealth Management LLC increased its holdings in shares of Charles River Laboratories International by 74.7% in the 3rd quarter. Venturi Wealth Management LLC now owns 262 shares of the medical research company’s stock worth $51,000 after buying an additional 112 shares during the last quarter. Finally, Provence Wealth Management Group bought a new position in shares of Charles River Laboratories International in the 3rd quarter valued at about $57,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

CRL has been the topic of several analyst reports. Evercore ISI boosted their price objective on Charles River Laboratories International from $260.00 to $265.00 and gave the stock an “outperform” rating in a research note on Thursday, February 15th. Citigroup increased their price target on Charles River Laboratories International from $215.00 to $250.00 and gave the company a “neutral” rating in a report on Thursday, February 15th. Guggenheim lowered shares of Charles River Laboratories International from a “buy” rating to a “neutral” rating in a research note on Thursday, February 15th. JPMorgan Chase & Co. boosted their price objective on shares of Charles River Laboratories International from $270.00 to $280.00 and gave the company an “overweight” rating in a research report on Thursday, February 15th. Finally, UBS Group raised their price objective on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the stock a “buy” rating in a research note on Thursday, February 15th. Five analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $253.38.

Charles River Laboratories International Stock Performance

Charles River Laboratories International stock opened at $230.11 on Friday. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.16 and a current ratio of 1.52. The company has a market capitalization of $11.85 billion, a PE ratio of 24.98, a P/E/G ratio of 1.83 and a beta of 1.44. The company has a 50 day moving average price of $250.70 and a 200-day moving average price of $225.27. Charles River Laboratories International, Inc. has a fifty-two week low of $161.65 and a fifty-two week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Thursday, May 9th. The medical research company reported $2.27 earnings per share for the quarter, beating analysts’ consensus estimates of $2.05 by $0.22. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $997.24 million. As a group, equities analysts forecast that Charles River Laboratories International, Inc. will post 11.01 earnings per share for the current year.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 5,882 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the transaction, the executive vice president now directly owns 2,596 shares in the company, valued at approximately $626,155.20. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, EVP Shannon M. Parisotto sold 5,882 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the completion of the sale, the executive vice president now owns 2,596 shares of the company’s stock, valued at approximately $626,155.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP William D. Barbo sold 4,050 shares of the stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $248.50, for a total transaction of $1,006,425.00. Following the transaction, the vice president now owns 22,879 shares in the company, valued at $5,685,431.50. The disclosure for this sale can be found here. Insiders sold a total of 14,932 shares of company stock valued at $3,693,663 over the last three months. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).